GENERIC AND SELECTED BRAND NAME DRUG DATA (samples of over 1200 listed)
Abacavir (Ziagen)WARNING: Allergy (fever, rash, fatigue, GI, resp) reported; stop drug immediately & do not rechallenge; lactic acidosis & hepatomegaly/steatosis reported Uses: *HIV Infxn* Action: NRTI Dose: Adults. 300 mg PO bid or 600 mg PO daily Peds. 8 mg/kg bid Caution: [C, –] CDC recommends HIV-infected mothers not breast-feed (transmission risk) Disp: Tabs 300 mg; soln 20 mg/mL SE: See Warning, ↑ LFTs, fat redistribution Notes: Numerous drug interactions.
Abatacept (Orencia)Uses:* Mod/severe RA w/inadequate response to one or more DMARDs Action: Selective costimulation modulator, ↓ T-cell activation Dose: Initial 500 mg (<60 kg), 750 mg(60–100 kg); 1 gm (>100kg) IV over 30 min; repeat at 2 and 4 wk, then every 4 wk Caution: w/TNF blockers[C; ?/-] COPD; h/o recurrent/localized/chronic, /predisposition to Infxn Contra: w/TNF antagonists (Increase Infxn); w/live vaccines w/in 3 mo of D/C abatacept Disp: IV powder: 250 mg/10 mL SE: HA, URI, N, nasopharyngitis, Infxn, malignancy, inf Rxns/hypersensitivity (dizziness, HA, HTN), COPD exacerbations, cough,dyspnea Notes: Screen for TB prior to use
Abciximab (ReoPro)Uses: *Prevent acute ischemic comps in PTCA,* MI Action: ↓plt aggregation (glycoprotein IIb/IIIa inhibitor) Dose: Unstable angina w/ planned PCI (ECC 2005): 0.25 mg/kg bolus, then 10 mcg/min cont inf X 18–24 h, stop 1 h after PCI; PCI: 0.25 mg/kg bolus 10–60 min pre PTCA, then 0.125 mcg/kg/min (max = 10 mcg/min) cont inf for 12 h;Caution:[C, ?/–] Contra: Active or recent (w/in 6 wk) internal hemorrhage, CVA w/in 2 y or CVA w/ significant neurologic deficit, bleeding diathesis or PO anticoagulants w/in 7 d (unless PT <1.2 X control), ↓plt (<100,000 cells/mcL), recent trauma or major surgery (w/in 6 wk), CNS tumor, AVM, aneurysm, severe uncontrolled HTN, vasculitis, use of dextran prior to or during PTCA, allergy to murine proteins Disp: Inj 2 mg/mL SE: Allergic Rxns, bleeding, ↓plt Notes: Use w/ heparin/ASA